JPH0768111B2 - Oral composition - Google Patents
Oral compositionInfo
- Publication number
- JPH0768111B2 JPH0768111B2 JP2059522A JP5952290A JPH0768111B2 JP H0768111 B2 JPH0768111 B2 JP H0768111B2 JP 2059522 A JP2059522 A JP 2059522A JP 5952290 A JP5952290 A JP 5952290A JP H0768111 B2 JPH0768111 B2 JP H0768111B2
- Authority
- JP
- Japan
- Prior art keywords
- lys
- arg
- peptide
- gly
- tyr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Landscapes
- Cosmetics (AREA)
Description
【発明の詳細な説明】 産業上の利用分野 本発明は口腔内細菌の歯牙および歯周組織への付着を抑
制する効果を有し、かつ、う蝕および歯周病の予防、治
療効果を有する口腔用組成物に関する。TECHNICAL FIELD The present invention has an effect of suppressing adhesion of oral bacteria to teeth and periodontal tissues, and also has an effect of preventing and treating caries and periodontal disease. It relates to a composition for oral cavity.
従来の技術および課題 う蝕や歯周病は、ある種の口腔内細菌が原因で発症する
ことが明らかであり、例えば、バクテロイデス・ジンジ
バリス（Bacteroides gingivalis）等の歯周病原性菌は
歯牙や歯周組織に付着、定着し、それらの菌の産生する
酵素や内毒素等により歯周組織を破壊し、歯周病を引き
起こす。Conventional techniques and problems It is clear that dental caries and periodontal disease are caused by certain oral bacteria. For example, periodontopathic bacteria such as Bacteroides gingivalis are teeth and teeth. It attaches to and adheres to the periodontal tissues, destroys the periodontal tissues by enzymes and endotoxins produced by these bacteria, and causes periodontal disease.
そのため、歯周病の発症を防止する目的でバクテロイデ
ス・ジンジバリスの付着を抑制する方法が検討され、例
えば、アミノ酸の一種であるアルギニンやリジンが該細
菌の頬粘膜上皮細胞への付着を抑制する等の報告がある
（口腔衛生学会誌38:590〜591、1988）。しかしなが
ら、これらは対象とする細胞が歯周組織由来のものでな
かったり、また、その効果が弱いという問題がある。Therefore, a method of suppressing the adhesion of Bacteroides gingivalis for the purpose of preventing the development of periodontal disease has been investigated, for example, arginine and lysine, which are one of the amino acids, suppress the adhesion of the bacterium to the buccal mucosal epithelial cells. Has been reported (Journal of Oral Hygiene 38: 590-591, 1988). However, these cells have a problem that the target cells are not derived from periodontal tissue and the effect is weak.
このような事情に鑑み、本発明者らは、う蝕および歯周
病の予防、治療に有効な薬剤について種々、検討したと
ころ、意外にも、特定のペプチドが適していることを見
出し、本発明を完成するに至った。In view of such circumstances, the present inventors have variously studied drugs effective for the prevention and treatment of dental caries and periodontal disease, and surprisingly found that a specific peptide is suitable, The invention was completed.
課題を解決するための手段 本発明は、分子内に塩基性アミノ酸が２つ以上連続して
結合したペプチド部分を１ヶ所以上有する合計３〜34個
のアミノ酸からなるペプチドを配合してなる口腔用組成
物を提供するものである。Means for Solving the Problems The present invention relates to an oral cavity prepared by blending a peptide consisting of a total of 3 to 34 amino acids having one or more peptide moieties in which two or more basic amino acids are continuously bound in a molecule. A composition is provided.
該ペプチドはバクテロイデス・ジンジバリス等の歯牙や
歯周組織への付着を効果的に抑制するので、本発明の口
腔用組成物はう蝕や歯周病の予防、治療用の歯磨剤や医
薬品として有用である。なお、本明細書で用いるペプチ
ドの構成アミノ酸およびその保護基等についての略号は
ペプチドの分野で通常用いられるものである。例えば、
Glyはグリシン、Hisはヒスチジン、Lysはリジン、Argは
アルギニン、Proはプロリン、Gluはグルタミン酸、Gln
はグルタミン、Serはセリン、Asnはアスパラギン、Val
はバリン、Ileはイソロイシン、Leuはロイシン、Tyrは
チロシン、Bocはｔ−ブトキシカルボニルを表す。Since the peptide effectively suppresses adhesion of Bacteroides gingivalis and the like to teeth and periodontal tissues, the oral composition of the present invention is useful as a dentifrice or a drug for the prevention and treatment of dental caries and periodontal disease. Is. The abbreviations for the constituent amino acids of the peptides used in the present specification and their protecting groups are those commonly used in the field of peptides. For example,
Gly is glycine, His is histidine, Lys is lysine, Arg is arginine, Pro is proline, Glu is glutamic acid, and Gln.
Is glutamine, Ser is serine, Asn is asparagine, Val
Represents valine, Ile represents isoleucine, Leu represents leucine, Tyr represents tyrosine, and Boc represents t-butoxycarbonyl.
用いるペプチドは、分子内に塩基性アミノ酸、好ましく
は、アルギニン、リジン、ヒスジンが２つ以上、好まし
くは２〜４つ連続して結合したペプチド部分を１ヶ所以
上有する合計７〜34個のアミノ酸、好ましくは７〜24個
のアミノ酸からなるものである。かかるペプチドは、例
えば、後記の参考例に示すように、公知の方法によって
容易に合成できる。代表的なものとしては、Arg−Lys−
Arg−Ala−Arg−Lys−Glu、Lys−Arg−Gln−His−Pro−
Gly−Lys−Arg、Cys−Lys−Arg−Gln−His−Pro−Gly−
Lys−Arg−Cys、Lys−Lys−Arg−Pro−Gln−Arg−Ala−
Thr−Ser−Asn−Val−Phe−Ser、Ser−Tyr−Ser−Met−
Glu−His−Phe−Arg−Trp−Gly−Lys−Pro−Val−Gly−
Lys−Lys−Arg−Arg−Pro−Val−Lys−Val−Tyr−Pro、
Ala−Val−Ser−Glu−Ile−Gln−Leu−Met−His−Asn−
leu−Gly−Lys−His−Leu−Ala−Ser−Val−Glu−Arg−
Met−Gln−Trp−Leu−Arg−Lys−Lys−Leu−Gln−Asp−
Val−His−Asn−Phe、His−Arg−Gly−Tyr、Lys−His−
His−Ser−His−Arg−Gly−Tyr、Gly−Tyr−Lys−Arg−
Lys−Phe−His−Glu−Lys−His−His−Ser−His−Arg−
Gly−Tyr、Asp−Ser−His−Ala−Lys−Arg−His−His−
Gly−Tyr−Lys−Arg−Lys−Phe−His−Glu−Lys−His−
His−Ser−His−Arg−Gly−Tyrおよびこれらの−COOHお
よび−NH2における製剤上許容される塩が挙げられる。The peptide to be used is a basic amino acid in the molecule, preferably 2 or more of arginine, lysine and histidine, preferably 7 to 34 amino acids in total having 1 or more peptide moieties having 2 to 4 consecutive bonds, It is preferably composed of 7 to 24 amino acids. Such a peptide can be easily synthesized by a known method, for example, as shown in the reference example below. A typical example is Arg-Lys-
Arg-Ala-Arg-Lys-Glu, Lys-Arg-Gln-His-Pro-
Gly-Lys-Arg, Cys-Lys-Arg-Gln-His-Pro-Gly-
Lys-Arg-Cys, Lys-Lys-Arg-Pro-Gln-Arg-Ala-
Thr-Ser-Asn-Val-Phe-Ser, Ser-Tyr-Ser-Met-
Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-Gly-
Lys-Lys-Arg-Arg-Pro-Val-Lys-Val-Tyr-Pro,
Ala-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-
leu-Gly-Lys-His-Leu-Ala-Ser-Val-Glu-Arg-
Met-Gln-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-
Val-His-Asn-Phe, His-Arg-Gly-Tyr, Lys-His-
His-Ser-His-Arg-Gly-Tyr, Gly-Tyr-Lys-Arg-
Lys-Phe-His-Glu-Lys-His-His-Ser-His-Arg-
Gly-Tyr, Asp-Ser-His-Ala-Lys-Arg-His-His-
Gly-Tyr-Lys-Arg-Lys-Phe-His-Glu-Lys-His-
His-Ser-His-Arg- Gly-Tyr and acceptable salts formulated in these -COOH and -NH 2 and the like.
本発明の口腔用組成物においては、これらペプチドは単
独で、あるいは２種以上組合せて用いることができ、組
成物中の該ペプチド配合量は0.001〜５重量％、特に0.0
1〜0.5重量％が好ましい。In the composition for oral cavity of the present invention, these peptides may be used alone or in combination of two or more kinds, and the compounding amount of the peptide in the composition is 0.001 to 5% by weight, particularly 0.0
1 to 0.5% by weight is preferred.
本発明の口腔用組成物は常法に従って、練歯磨、粉歯
磨、液状歯磨、マウスウオッシュ、チュウインガム、う
がい液、トローチ、パスタ、クリーム、軟膏剤、貼付
剤、錠剤のごとき歯磨類や医薬品とすることができる。
他の配合成分は特に限定するものではなく、通常、この
種の組成物に用いられる成分を配合できる。例えば、練
歯磨であれば研磨剤、粘結剤、湿潤剤、甘味剤、香料、
防腐剤、他の薬効剤等が適宜配合される。Oral composition of the present invention, according to a conventional method, toothpaste, powder toothpaste, liquid toothpaste, mouthwash, chewing gum, mouthwash, troche, pasta, cream, ointment, patch, toothpaste and pharmaceuticals such as tablets be able to.
The other compounding ingredients are not particularly limited, and the ingredients usually used in this type of composition can be compounded. For example, for toothpaste, abrasives, binders, wetting agents, sweeteners, flavors,
Preservatives, other medicinal agents and the like are appropriately mixed.
医薬品の場合、内服の場合は、成人１日当たり、ペプチ
ド量として５〜50mg、外用の場合、ペプチド量として１
回に１〜数10mgの用量で、有害な副作用なしにう蝕や歯
周病の予防、治療に用いることができ、歯磨類の場合
は、これらの用量を勘案して常法に従って使用する。In the case of medicines, the daily dose for adults is 5 to 50 mg per day for oral use, and the peptide amount is 1 for external use.
It can be used at a dose of 1 to several tens of mg at a time for the prevention and treatment of dental caries and periodontal disease without harmful side effects. In the case of dentifrice, these doses are taken into consideration and used according to a conventional method.
作用 以下、実験により本発明に用いるペプチドの作用を具体
的に示す。Action Hereinafter, the action of the peptide used in the present invention will be specifically shown by experiments.
（実験１） 歯肉上皮細胞へのバクテロイデス・ジンジバリス381株
の付着に及ぼす影響 嫌気条件下で、48時間培養したバクテロイデス・ジンジ
バリス381株を0.15M NaClを含む10mMリン酸塩緩衝液（p
H7.0、PBS）にてよく洗浄した後、PBSに懸濁した。一
方、ヒト歯肉上皮細胞を歯周炎の認められない成人より
採取し、よく洗浄した後、PBSに懸濁した。該細菌懸濁
液（１×108菌体/ml）と上皮細胞懸濁液（１×105細胞/
ml）を1mlずつ混合し、37℃で30分間、振盪しながらイ
ンチューベートし、バクテロイデス・ジンジバリス381
株の人歯肉上皮細胞への付着反応を行わせた。反応終了
後、上皮細胞を穴径12μｍのメンブレンフィルターにて
集めた。集めた上皮細胞をPBSに懸濁し、ガラススライ
ドに塗抹し、自然乾燥させた後、火炎固定してゲンチア
ナバイオレットで染色した。上皮細胞に付着した菌体数
を、光学顕微鏡下（倍率10〜40）で無作為に30個の上皮
細胞を選び、上皮細胞２個当たりの付着菌数で算定し
た。また、陰性対照として、上皮細胞をPBSのみと反応
させ、上皮細胞に初めから付着していた細菌数を求めて
陰性対照値とし、バクテロイデス・ジンジバリスの上皮
細胞への付着数として、前記算定値から陰性対照値を差
し引いた値を用いた。バクテロイデス・ジンジバリスの
上皮細胞への付着に及ぼすペプチドの影響はバクテロイ
デス・ジンジバリスを予め室温にて15時間、これらの物
質と反応させた後、前記と同様の方法で調べた。結果を
以下の第１表に示す。(Experiment 1) Effect on Adhesion of Bacteroides gingivalis 381 Strain to Gingival Epithelial Cells Under anaerobic condition, Bacteroides gingivalis 381 strain was cultivated for 48 hours under a 10 mM phosphate buffer solution containing 0.15 M NaCl (p
After washing well with H7.0, PBS), the cells were suspended in PBS. On the other hand, human gingival epithelial cells were collected from an adult without periodontitis, washed well, and then suspended in PBS. The bacterial suspension (1 × 10 8 cells / ml) and epithelial cell suspension (1 × 10 5 cells / ml)
1 ml each) and incubated at 37 ° C for 30 minutes with shaking, and Bacteroides gingivalis 381
The strain was allowed to react with human gingival epithelial cells. After the reaction was completed, epithelial cells were collected by a membrane filter having a pore size of 12 μm. The collected epithelial cells were suspended in PBS, smeared on a glass slide, naturally dried, fixed with flame, and stained with gentian violet. The number of bacterial cells attached to the epithelial cells was calculated by randomly selecting 30 epithelial cells under an optical microscope (magnification: 10 to 40) and the number of adherent cells per 2 epithelial cells. Also, as a negative control, the epithelial cells were reacted only with PBS, and the number of bacteria that had originally adhered to the epithelial cells was determined as the negative control value, and the number of adherence to the epithelial cells of Bacteroides gingivalis was calculated from the above calculated values. The value obtained by subtracting the negative control value was used. The effect of the peptide on the adhesion of Bacteroides gingivalis to epithelial cells was examined by the same method as above after reacting Bacteroides gingivalis with these substances for 15 hours at room temperature in advance. The results are shown in Table 1 below.
第１表に示すごとく、比較例のペプチドでは抑制は認め
られなかったが、本発明に用いるペプチドは細胞の上皮
細胞への付着を著しく抑制した。 As shown in Table 1, no inhibition was observed with the peptides of Comparative Examples, but the peptides used in the present invention significantly inhibited the adhesion of cells to epithelial cells.
（実験２） 唾液被覆ヒドロキシアパタイト（HAP）ビーズ上へのバ
クテロイデス・ジンジバリス381株の付着に及ぼす影響 20mgのHAPビーズをヒトの唾液（血液型Ｏ）0.5mlととも
に室温にて１時間インキュベートした。該ビーズを0.05
M KCl、1mM KH2−PO4、1mM CaCl2および1mM MgCl2から
なるpH6.0の緩衝液（この緩衝液は、唾液無機成分のモ
デルである）1mlで２回洗浄した。ついで、室温にて、
該ビーズをpH7.0の試料溶液0.5mlとともに１時間インキ
ュベートし、前記緩衝液1mlで２回洗浄した。(Experiment 2) Effect on adhesion of Bacteroides gingivalis strain 381 strain on saliva-coated hydroxyapatite (HAP) beads 20 mg of HAP beads was incubated with 0.5 ml of human saliva (blood group O) at room temperature for 1 hour. 0.05 for the beads
The cells were washed twice with 1 ml of a buffer solution containing M KCl, 1 mM KH 2 —PO 4 , 1 mM CaCl 2 and 1 mM MgCl 2 at pH 6.0 (this buffer solution is a model of salivary inorganic components). Then, at room temperature,
The beads were incubated with 0.5 ml of pH 7.0 sample solution for 1 hour and washed twice with 1 ml of the above buffer.
つぎに、前記緩衝液0.5ml中に［3H］チミジン標識バク
テリア（バクテロイデス・ジンジバリス）を5.0×107個
含む懸濁液を該ビーズに添加し、室温にて１時間インキ
ュベートした。前記緩衝液1mlで３回洗浄し、ビーズを
バイアルに移し、液体シンチュレーションカウンターを
用いて放射能を計測した。一方、既知の［3H］標識細胞
の割合を同じ方法で計数し、バクテリア数の検量線を作
成した。結果を以下の第２表に示す。Next, a suspension containing 5.0 × 10 7 [ 3 H] thymidine-labeled bacteria (Bacteroides gingivalis) in 0.5 ml of the above-mentioned buffer was added to the beads and incubated at room temperature for 1 hour. After washing 3 times with 1 ml of the above buffer, the beads were transferred to a vial, and the radioactivity was measured using a liquid scintillation counter. On the other hand, the ratio of known [ 3 H] -labeled cells was counted by the same method, and a calibration curve for the number of bacteria was prepared. The results are shown in Table 2 below.
第２表に示すごとく、本発明に用いるペプチドにより細
菌の唾液被覆HAPへの付着が著しく抑制された。 As shown in Table 2, the peptides used in the present invention markedly suppressed the adhesion of bacteria to saliva-coated HAP.
（実験３） バクテロイデス・ジンジバリスの付着阻害におけるペプ
チドの濃度依存性 種々の濃度を有するペプチド用い、実験１の方法と同様
にペプチドによるバクテロイデス・ジンジバリスの歯肉
上皮細胞への付着阻害効果を調べた。結果を以下の第３
表に示す。(Experiment 3) Concentration Dependence of Peptide on Adhesion Inhibition of Bacteroides gingivalis Using peptides having various concentrations, the inhibitory effect of Bacteroides gingivalis on gingival epithelial cells was investigated in the same manner as in Experiment 1. The result is the third
Shown in the table.
第３表に示すごとく、濃度0.001mMにおいてもペプチド
の付着阻害効果が認められた。 As shown in Table 3, the peptide adhesion inhibitory effect was observed even at a concentration of 0.001 mM.
（実験４） ペプチドによる歯周局所へのバクテロイデス・ジンジバ
リスの定着阻害効果 ５週令の無菌ハムスター６匹を２群に分け、実験開始
日、第１群のハムスターの下顎臼歯に綿棒で0.1mM薬液
を塗布し、第２群には対照としてPBSを塗布した。引き
続き、対象の臼歯に結紮糸を施し、約109/mlに調製した
バクテロイデス・ジンジバリスESO132株生菌液を投与し
た。(Experiment 4) Peptide inhibits colonization of Bacteroides gingivalis in the periodontal region Six 5-week-old sterile hamsters were divided into 2 groups, and on the day of the experiment, a 0.1 mM chemical solution was applied to the lower molars of the hamsters of the 1st group with a cotton swab. Was applied, and PBS was applied to the second group as a control. Subsequently, a ligature was applied to the target molars, and a Bacteroides gingivalis ESO132 strain viable bacterium solution prepared to about 10 9 / ml was administered.
その後、薬液およびPBS溶液の塗布は１日１回で、毎日
行い、菌液の投与は１週間に２回の割合で６週間にわた
って行った。Thereafter, application of the drug solution and the PBS solution was performed once a day, every day, and the administration of the bacterial solution was performed twice a week for 6 weeks.
最終菌液投与後、１週間後に被験部位の歯肉の炎症の程
度を観察すると共に、結紮糸をはずした後、その部位の
プラークをキュレットで採取し、嫌気的に保持したリン
ガー液に懸濁し、このサンプル中のバクテロイデス・ジ
ンジバリス数を培養法により計数した。結果を以下の第
４表に示す。After the administration of the final bacterial solution, one week later, the degree of inflammation of the gingiva at the test site was observed, and after removing the ligature, the plaque at that site was collected with a curette and suspended in Ringer's solution anaerobically retained. The number of Bacteroides gingivalis in this sample was counted by the culture method. The results are shown in Table 4 below.
第４表に示すごとく、薬液処理群では、対照群に比べて
歯周局所へのバクテロイデス・ジンジバリスの定着が著
しく抑制されると共に、歯肉の炎症の程度も軽かった。 As shown in Table 4, in the chemical solution-treated group, the establishment of Bacteroides gingivalis in the periodontal region was significantly suppressed and the degree of gingival inflammation was also lower than in the control group.
実施例 つぎに参考例および実施例を挙げて本発明をさらに詳し
く説明する。実施例中、「％」はいずれも重量％であ
る。EXAMPLES Next, the present invention will be described in more detail with reference to Reference Examples and Examples. In the examples, "%" is% by weight.
参考例 用いたペプチドはBoc−アミノ酸無水物法を採用してい
るABIペプチドシンセサイザー430Aを用いて固相法によ
り合成した。側鎖を保護したBoc−アミノ誘導体はAsp
（ＯｃHex）、Ser（Bzl）、His（π−Bom）、Lys（１−
ｚ）、Arg（Tos）、Tyr（Br−Ｚ）およびGlu（ＯｃHe
x）であり、合成の出発物質としてBoc−Tyr（Br−Ｚ）
−PAM樹脂を用いたペプチド鎖の組み立てが終了した
後、ペプチドが結合した樹脂を10％アニソールを含む無
水HFで、０℃にて75分処理した。HFを蒸発させた後、遊
離したペプチドを５％酢酸で抽出し、凍結乾燥した。粗
ペプチドはODSカラムで精製し、凍結乾燥した。つい
で、得られたペプチドを塩酸110℃にて24時間加水分解
し、各々、アミノ酸含量を測定した。代表的なペプチド
のアミノ酸含量を以下に示す。Reference Example The peptide used was synthesized by the solid-phase method using ABI peptide synthesizer 430A adopting the Boc-amino acid anhydride method. The side-chain protected Boc-amino derivative is Asp
(O c Hex), Ser (Bzl), His (π-Bom), Lys (1-
z), Arg (Tos), Tyr (Br-Z) and Glu (O c He
x), and Boc-Tyr (Br-Z) as the starting material for the synthesis
-After the assembly of the peptide chain using PAM resin was completed, the peptide-bonded resin was treated with anhydrous HF containing 10% anisole at 0 ° C for 75 minutes. After evaporating the HF, the liberated peptide was extracted with 5% acetic acid and lyophilized. The crude peptide was purified by ODS column and lyophilized. Then, the obtained peptides were hydrolyzed at 110 ° C. for 24 hours, and the amino acid content of each was measured. The amino acid contents of representative peptides are shown below.
実施例１（練歯磨） つぎの処方により、常法に従って練歯磨を製造した。 Example 1 (Toothpaste) A toothpaste was produced according to a conventional method according to the following formulation.
成 分 配合量（重量％） 第二リン酸カルシウム 45.0 カルボキシメチル Lys−His−His−Ser−His−Arg−Gly−Tyr 0.5 Gly−Tyr−Lys−Arg−Lys−Phe−His−Glu−Lys−His−
His−Ser−His−Arg−Gly−Tyr 0.5 セルロースナトリウム 0.5 グリセリン 20.0 ラウリル硫酸ナトリウム 1.5 サッカリンナトリウム 0.1 蒸留水 100％に調製 実施例２（練歯磨） つぎの処方により、常法に従って練歯磨を製造した。Component Ingredient (wt%) Dibasic calcium phosphate 45.0 Carboxymethyl Lys-His-His-Ser-His-Arg-Gly-Tyr 0.5 Gly-Tyr-Lys-Arg-Lys-Phe-His-Glu-Lys-His-
His-Ser-His-Arg-Gly-Tyr 0.5 Sodium cellulose 0.5 Glycerin 20.0 Sodium lauryl sulfate 1.5 Sodium saccharin 0.1 Prepared to 100% distilled water Example 2 (Toothpaste) A toothpaste was prepared by the following method according to a conventional method.
成 分 配合量（重量％） 炭酸カルシウム 45.0 Gly−Tyr−Lys−Arg−Lys−Phe−His−Glu−Lys−His−
His−Ser−His−Arg−Gly−Tyr 1.0 セルロースナトリウム 1.0 グリセリン 20.0 ラウリル硫酸ナトリウム 1.5 サッカリンナトリウム 0.1 香料 1.2 蒸留水 100％に調製 実施例３（マウスウオッシュ） つぎの処方により、常法に従ってマウスウオッシュを製
造した。Component Blending amount (wt%) Calcium carbonate 45.0 Gly-Tyr-Lys-Arg-Lys-Phe-His-Glu-Lys-His-
His-Ser-His-Arg-Gly-Tyr 1.0 Sodium cellulose 1.0 Glycerin 20.0 Sodium lauryl sulfate 1.5 Sodium saccharin 0.1 Perfume 1.2 Prepared in 100% distilled water Example 3 (mouthwash) A mousewash was produced according to a conventional method according to the following method. did.
成 分 配合量（重量％） エタノール 10.0 Lys−His−His−Ser−His−Arg−Gly−Tyr 0.1 ポリオキシエチレン（60EO） 0.5 硬化ヒマシ油 モノオレイン酸ポリオキシエチレン 0.5 （20EO）ソルビタン サッカリンナトリウム 0.2 防腐剤および香料 0.8 蒸留水 100％に調製 実施例４（マウスウオッシュ） つぎの処方により、常法に従ってマウスウオッシュを製
造した。Component Blend (wt%) Ethanol 10.0 Lys-His-His-Ser-His-Arg-Gly-Tyr 0.1 Polyoxyethylene (60EO) 0.5 Hardened castor oil Polyoxyethylene monooleate 0.5 (20EO) sorbitan Saccharin sodium 0.2 Antiseptic Agent and fragrance 0.8 Prepared in 100% distilled water Example 4 (mouthwash) A mouthwash was produced according to a conventional method according to the following formulation.
成 分 配合量（重量％） エタノール 15 グリセリン 15 ポリオキシエチレン（60EO） 1 硬化ヒマシ油 Asp−Ser−His−Ala−Lys−Arg−His−His−Gly−Tyr−
Lys−Arg−Lys−Phe−His−Glu−Lys−His−His−Ser−
His−Arg−Gly−Tyr 0.05 塩化セチルピリジニウム 0.05 サッカリンナトリウム 0.1 香料 0.5 蒸留水 100％に調製 実施例５（口腔用パスタ） つぎの処方により、常法に従って口腔用パスタを製造し
た。Component Blend (wt%) Ethanol 15 Glycerin 15 Polyoxyethylene (60EO) 1 Hydrogenated castor oil Asp-Ser-His-Ala-Lys-Arg-His-His-Gly-Tyr-
Lys-Arg-Lys-Phe-His-Glu-Lys-His-His-Ser-
His-Arg-Gly-Tyr 0.05 Cetylpyridinium chloride 0.05 Saccharin sodium 0.1 Perfume 0.5 Prepared in 100% distilled water Example 5 (oral pasta) An oral pasta was produced according to a conventional method according to the following formulation.
成 分 配合量（重量％） 白色ワセリン 10.0 ステアリンアルコール 8.0 プロピレングリコール 5.6 ラウリル硫酸ナトリウム 0.6 パラオキシ安息香酸エチル 0.01 蒸留水 16.0 Lys−His−His−Ser−His−Arg−Gly−Tyr 2.0 カルボキシメチルセルロース 100％に調製 ナトリウム 発明の効果 本発明によれば、う蝕および歯周病の予防、治療に有用
な口腔用組成物が得られる。Ingredients Content (wt%) White petrolatum 10.0 Stearic alcohol 8.0 Propylene glycol 5.6 Sodium lauryl sulfate 0.6 Ethyl paraoxybenzoate 0.01 Distilled water 16.0 Lys-His-His-Ser-His-Arg-Gly-Tyr 2.0 Carboxymethylcellulose 100% Preparation Sodium Effect of the Invention According to the present invention, an oral composition useful for prevention and treatment of dental caries and periodontal disease can be obtained.
Claims (1)
て結合したペプチド部分を１ケ所以上有する合計７〜34
個のアミノ酸からなるペプチドを配合してなることを特
徴とする口腔用組成物。1. A total of 7 to 34 having one or more peptide moieties in which two or more basic amino acids are continuously bound in the molecule.
A composition for oral cavity comprising a peptide consisting of individual amino acids.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2059522A JPH0768111B2 (en) | 1990-03-09 | 1990-03-09 | Oral composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2059522A JPH0768111B2 (en) | 1990-03-09 | 1990-03-09 | Oral composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH03261717A JPH03261717A (en) | 1991-11-21 |
| JPH0768111B2 true JPH0768111B2 (en) | 1995-07-26 |
Family
ID=13115684
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2059522A Expired - Lifetime JPH0768111B2 (en) | 1990-03-09 | 1990-03-09 | Oral composition |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH0768111B2 (en) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH04182420A (en) * | 1990-11-19 | 1992-06-30 | Sangi Co Ltd | Precantive and therapeutic treatment agent for periodontosis |
| JP3566374B2 (en) * | 1994-02-03 | 2004-09-15 | 花王株式会社 | Oral composition |
| DE69528445D1 (en) * | 1994-12-12 | 2002-11-07 | Unilever Nv | Anti-microbial agent |
| EP0721774B1 (en) * | 1994-12-12 | 2002-10-02 | Unilever N.V. | Anti-microbial compositions |
| AU740610B2 (en) * | 1996-12-27 | 2001-11-08 | Chugai Seiyaku Kabushiki Kaisha | Orthodontic remedies containing PTH |
| WO1999004808A1 (en) * | 1997-07-22 | 1999-02-04 | Chugai Seiyaku Kabushiki Kaisha | Dental remedies containing pth |
| JP3726875B2 (en) * | 1999-09-14 | 2005-12-14 | ライオン株式会社 | Periodontal disease bacterial endotoxin neutralizer, periodontal disease causative agent inhibitor and oral composition |
| US7592304B2 (en) | 1999-10-01 | 2009-09-22 | Dmi Life Sciences, Inc. | Metal-binding compounds and uses therefor |
| JP4761014B2 (en) * | 2001-02-26 | 2011-08-31 | ライオン株式会社 | Oral composition |
| JP4709735B2 (en) * | 2006-12-04 | 2011-06-22 | 花王株式会社 | Coaggregation inhibitor of oral bacteria |
| WO2009087117A1 (en) | 2008-01-07 | 2009-07-16 | Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patiëntenzorg | Use of peptides for promoting wound healing |
| US9090670B2 (en) | 2008-01-07 | 2015-07-28 | Rapid Pathogen Screening, Inc. | Use of peptides for promoting wound healing |
| CN101938990A (en) * | 2008-02-08 | 2011-01-05 | 高露洁-棕榄公司 | Compositions and methods comprising basic amino acid peptides and proteases |
| BRPI0907109A2 (en) * | 2008-02-08 | 2016-05-03 | Colgate Palmolive Co | dental handkerchief and method |
| US9561168B2 (en) * | 2011-12-15 | 2017-02-07 | Colgate-Palmolive Company | Oral care compositions |
| US20130310327A1 (en) | 2012-05-18 | 2013-11-21 | Rapid Pathogen Screening, Inc. | Histatin for Corneal Wound Healing and Ocular Surface Disease |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA773318B (en) * | 1976-06-18 | 1978-04-26 | I Kleinberg | Means and method for improving natural defenses against caries |
| JP2641742B2 (en) * | 1988-08-18 | 1997-08-20 | マルハ株式会社 | New peptides and antibacterial agents |
-
1990
- 1990-03-09 JP JP2059522A patent/JPH0768111B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JPH03261717A (en) | 1991-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4725576A (en) | Fungicidal polypeptide compositions containing L-histidine and methods for use therefore | |
| JP5684454B2 (en) | Oral care therapeutic and prophylactic compositions | |
| JPH0768111B2 (en) | Oral composition | |
| AU2021269317B2 (en) | Treatment for gingivitis | |
| US20210121380A1 (en) | Amino Acid Containing Oral Care Composition for Treating Caries By Reducing Lactic Acid Release in Oral Biofilms | |
| WO2020079531A1 (en) | Acyl-n-methylglucamide containing oral care composition for treating caries by reducing lactic acid release in oral biofilms | |
| JP4730991B2 (en) | Oral composition | |
| JPS59225109A (en) | Composition for oral cavity application | |
| WO1998017236A1 (en) | Oral preparations containing biologically active crystallized glass | |
| KR980008210A (en) | Composition for promoting oral hygiene | |
| WO2018191533A1 (en) | Dental strips for the delivery of specifically targeted antimicrobial peptides | |
| JP2719024B2 (en) | Oral composition | |
| WO1998042297A1 (en) | Method of recalcifying teeth | |
| JPH08245353A (en) | Oral cavity composition | |
| JP2760573B2 (en) | Oral composition for inhibiting plaque adhesion | |
| JPH03261716A (en) | Composition for oral cavity application | |
| JPS62263115A (en) | Composition for oral cavity | |
| JPH04300816A (en) | Composition for oral cavity | |
| JPH03178926A (en) | Composition for oral cavity application | |
| JPH07165547A (en) | Composition for oral cavity | |
| JP3464807B2 (en) | Toothpaste composition | |
| JPS61130212A (en) | Composition for oral cavity | |
| JPH0558866A (en) | Composition for oral cavity | |
| JPH10152424A (en) | Composition for oral cavity | |
| JPH03178925A (en) | Composition for oral cavity application |